RTX (RTX) Q4 24/25 earnings summary

Executive summary

• Regained profitable growth with revenue up 10% year-over-year to DKK 547 million, driven by strong performance in enterprise (up 21%) and healthcare (up 43%) segments.

• Gross margin improved by 3.3 percentage points to 50%-51% for the year, supported by product/customer mix and cost optimization.

• EBITDA increased significantly to DKK 35.5 million from DKK 3.1 million year-over-year, reflecting operational improvements.

• Net liquidity strengthened to over DKK 150 million at year-end, providing a solid financial foundation.

• Leadership transition completed with a new CEO appointed and strategic focus on long-term growth in healthcare and retail.

Financial highlights

• Annual revenue reached DKK 547 million, up 10% year-over-year (12% adjusted for USD effects).

• Gross margin: 50%-51% for the year, up from 46.7% last year.

• EBITDA: DKK 35.5 million, up from DKK 3.1 million year-over-year.

• Inventory reduced to DKK 37 million, and free cash flow improved to DKK 52.8 million.

• Negative impact from declining USD in the second half of the year.

Outlook and guidance

• Revenue guidance for next year set at DKK 575–625 million, with EBITDA expected between DKK 35 million and DKK 65 million.

• EBIT guidance ranges from DKK 0 to DKK 30 million, reflecting positive profitability expectations.

• Growth outlook supported by a strong pipeline, customer relationships, and new product launches.

• Continued investments in healthcare and next-generation enterprise platform planned.

• Key risks include macroeconomic volatility and USD exchange rate fluctuations.